Journal article
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
L Xiao, M Karsa, E Ronca, A Bongers, A Kosciolek, A El-Ayoubi, JL Revalde, JA Seneviratne, BB Cheung, LC Cheung, RS Kotecha, A Newbold, S Bjelosevic, GM Arndt, RB Lock, RW Johnstone, AV Gudkov, KV Gurova, M Haber, MD Norris Show all
Frontiers in Oncology | FRONTIERS MEDIA SA | Published : 2022
Abstract
Rearrangements of the Mixed Lineage Leukemia (MLL/KMT2A) gene are present in approximately 10% of acute leukemias and characteristically define disease with poor outcome. Driven by the unmet need to develop better therapies for KMT2A-rearranged leukemia, we previously discovered that the novel anti-cancer agent, curaxin CBL0137, induces decondensation of chromatin in cancer cells, delays leukemia progression and potentiates standard of care chemotherapies in preclinical KMT2A-rearranged leukemia models. Based on the promising potential of histone deacetylase (HDAC) inhibitors as targeted anti-cancer agents for KMT2A-rearranged leukemia and the fact that HDAC inhibitors also decondense chroma..
View full abstractGrants
Awarded by Cancer Council Victoria
Funding Acknowledgements
LX has received grants from Cancer Institute NSW (ECF171127), Tour de Cure and Neuroblastoma Australia. KS is supported by funding from the Kids Cancer Alliance (KCA). KS, MJH, MH, and MN are supported by a grant awarded through the Priority-driven Collaborative Cancer Research Scheme and co-funded by Cancer Australia and The Kids' Cancer Project (APP1164865) and philanthropy from Tenix Foundation. SB is supported by a Cancer Council Victoria (CCV) Postdoctoral Fellowship. The laboratory of RJ was supported by the Cancer Council of Victoria, National Health and Medical Research Council of Australia (NHMRC) and The Kids' Cancer Project, and the Peter MacCallum Foundation and Australian Cancer Research Foundation provide generous support for equipment and core facilities. RL is supported by National Health and Medical Research Council of Australia (NHMRC) Fellowships APP1059804 and APP1157871. MJH and MH are recipients of a grant from Anthony Rothe Memorial Trust for this work. MH and MN are supported by grants from NHMRC (APP1132608 and APP1085411), Cancer Institute NSW (14/TPG/1-13) and Cancer Council NSW (PG 16-01). LC and RK are supported by the Children's Leukemia and Cancer Research Foundation.